Trial Profile
A Phase II Study of ONC201 in Recurrent or Metastatic Type II Endometrial Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2022
Price :
$35
*
At a glance
- Drugs Dordaviprone (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- Sponsors Chimerix; Oncoceutics
- 08 Nov 2022 Planned primary completion date changed from 31 Aug 2022 to 31 Dec 2022.
- 10 Mar 2022 Planned End Date changed from 31 May 2022 to 31 Dec 2022.
- 10 Mar 2022 Planned primary completion date changed from 28 Feb 2022 to 31 Aug 2022.